JP7560476B2 - キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体 - Google Patents

キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体 Download PDF

Info

Publication number
JP7560476B2
JP7560476B2 JP2021559904A JP2021559904A JP7560476B2 JP 7560476 B2 JP7560476 B2 JP 7560476B2 JP 2021559904 A JP2021559904 A JP 2021559904A JP 2021559904 A JP2021559904 A JP 2021559904A JP 7560476 B2 JP7560476 B2 JP 7560476B2
Authority
JP
Japan
Prior art keywords
seq
cdr
antibody
variable region
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022528721A (ja
JP2022528721A5 (https=
Inventor
ヴィセンゾ ガラ ステファノ
エヴァン トンプソン ケネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abcuro Inc
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of JP2022528721A publication Critical patent/JP2022528721A/ja
Publication of JP2022528721A5 publication Critical patent/JP2022528721A5/ja
Application granted granted Critical
Publication of JP7560476B2 publication Critical patent/JP7560476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021559904A 2019-04-09 2020-04-09 キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体 Active JP7560476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831713P 2019-04-09 2019-04-09
US62/831,713 2019-04-09
PCT/US2020/027498 WO2020210512A1 (en) 2019-04-09 2020-04-09 Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Publications (3)

Publication Number Publication Date
JP2022528721A JP2022528721A (ja) 2022-06-15
JP2022528721A5 JP2022528721A5 (https=) 2023-04-17
JP7560476B2 true JP7560476B2 (ja) 2024-10-02

Family

ID=72748720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559904A Active JP7560476B2 (ja) 2019-04-09 2020-04-09 キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体

Country Status (13)

Country Link
US (3) US11180561B2 (https=)
EP (1) EP3952999A4 (https=)
JP (1) JP7560476B2 (https=)
KR (1) KR20210150506A (https=)
CN (1) CN114040800B (https=)
AU (1) AU2020272939A1 (https=)
BR (1) BR112021019128A2 (https=)
CA (1) CA3136625A1 (https=)
IL (1) IL287044A (https=)
MX (1) MX2021012171A (https=)
SG (1) SG11202110610VA (https=)
WO (1) WO2020210512A1 (https=)
ZA (1) ZA202107414B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004553A2 (pt) 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
WO2022204529A1 (en) * 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
CA3212311A1 (en) * 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2023009498A1 (en) * 2021-07-26 2023-02-02 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002372532A (ja) 2001-05-08 2002-12-26 Japan Science & Technology Corp Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ
JP2005508869A (ja) 2001-06-09 2005-04-07 メディカル リサーチ カウンスル 呼吸器合胞体ウイルス
JP2012025694A (ja) 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
JP2015518471A (ja) 2012-03-28 2015-07-02 ジェネンテック， インコーポレイテッド 抗ｈｃｍｖイディオタイプ抗体およびそれらの使用
WO2016013672A1 (ja) 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
WO2017210523A1 (en) 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
WO2018053264A2 (en) 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy
JP2018537090A (ja) 2015-11-17 2018-12-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 神経およびその他の障害の処置のための結合アゴニスト

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
AU2001245838A1 (en) 2000-03-17 2001-10-03 Gemini Science, Inc. Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
CN101668773B (zh) * 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
BR112018068103A2 (pt) * 2016-03-08 2019-01-15 Janssen Biotech Inc anticorpos gitr, métodos e usos
WO2019169229A1 (en) * 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002372532A (ja) 2001-05-08 2002-12-26 Japan Science & Technology Corp Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ
JP2005508869A (ja) 2001-06-09 2005-04-07 メディカル リサーチ カウンスル 呼吸器合胞体ウイルス
JP2012025694A (ja) 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
JP2015518471A (ja) 2012-03-28 2015-07-02 ジェネンテック， インコーポレイテッド 抗ｈｃｍｖイディオタイプ抗体およびそれらの使用
WO2016013672A1 (ja) 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
JP2018537090A (ja) 2015-11-17 2018-12-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 神経およびその他の障害の処置のための結合アゴニスト
WO2017210523A1 (en) 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
WO2018053264A2 (en) 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy

Also Published As

Publication number Publication date
US11180561B2 (en) 2021-11-23
EP3952999A4 (en) 2023-01-25
US12139541B2 (en) 2024-11-12
JP2022528721A (ja) 2022-06-15
SG11202110610VA (en) 2021-10-28
AU2020272939A1 (en) 2021-11-11
AU2020272939A8 (en) 2021-12-02
BR112021019128A2 (pt) 2022-01-04
MX2021012171A (es) 2021-12-10
ZA202107414B (en) 2023-02-22
WO2020210512A9 (en) 2020-11-19
IL287044A (en) 2021-12-01
US20220089747A1 (en) 2022-03-24
US20250101114A1 (en) 2025-03-27
US20200325233A1 (en) 2020-10-15
WO2020210512A1 (en) 2020-10-15
CN114040800B (zh) 2024-09-20
CA3136625A1 (en) 2020-10-15
CN114040800A (zh) 2022-02-11
EP3952999A1 (en) 2022-02-16
KR20210150506A (ko) 2021-12-10

Similar Documents

Publication Publication Date Title
JP7560476B2 (ja) キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体
JP6879947B2 (ja) 抗ｎｔｂ−ａ抗体及び関連組成物ならびに方法
AU2014298040B2 (en) Anti-CXCR4 antibodies and antibody-drug conjugates
JP6449777B2 (ja) 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
JP7295098B2 (ja) 新規抗ｃｄ１９抗体
CA2997809A1 (en) Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
CA2994214A1 (en) Humanized anti-ccr7 receptor antibodies
US20250074980A1 (en) Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
KR20230009459A (ko) 인간 ceacam1/3/5에 특이적으로 결합하는 신규 항체 및 그의 용도
US20250101112A1 (en) Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
CN120769866A (zh) 抗CD79b抗体及其用途
WO2022212836A1 (en) Gpnmb antibodies and methods of use
KR20230162798A (ko) 항-klrg1 항체
WO2026072990A1 (en) Methods of treating t-cell large granular lymphocytic leukemia
WO2025147544A1 (en) Methods of treating inclusion body myositis (ibm)
WO2025162471A1 (en) Antibodies and antibody-drug conjugates targeting ox40 and uses thereof
CN118271439A (zh) 抗CD79b抗体及其用途
BR122025029428A2 (pt) Anticorpo isolado anti-cd19, sequências de polinucleotídeo isolado e de ácido nucleico, vetores, célula hospedeira, método de expressar o anticorpo, conjugado anticorpo-droga, composição farmacêutica, uso do anticorpo, receptor de antígeno quimérico (car), célula t isolada, método para estimular uma resposta imune, e kit
HK1240603A1 (en) Anti-cd40 antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240827

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240919

R150 Certificate of patent or registration of utility model

Ref document number: 7560476

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150